Clinical Trials Directory

Trials / Completed

CompletedNCT06327503

Salivary Signal Molecules for Neural and Vascular Homeostasis in T2DM

Salivary Signal Molecules Relevant for Neural and Vascular Homeostasis in Patients With Type 2 Diabetes Mellitus

Status
Completed
Phase
Study type
Observational
Enrollment
24 (actual)
Sponsor
University of Belgrade · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Various signal molecules are detected in blood and tissues of patients with T2DM, that are important for the function of neural tissue in diabetic setting. Among them, specifically important are neuroprotective and neurotrophic growth factors such as nerve growth factor (NGF), glial cells - derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF). Furthermore, several other signal molecules are discovered to affect vascular tissues homeostasis in T2DM, including soluble alpha-klotho (s-Klotho), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). Most of these molecules are also detected in saliva in various states and diseases of orofacial system, but data about their levels in saliva of T2DM patients are lacking, although neural and vascular diabetic complications are present in orofacial tissues and organs. Also, there is no data about presence and levels of s-Klotho in saliva of healthy or T2DM patients, although it was reported that this molecule exerts protective effect on the salivary glands tissue. Salivary opiorphin is recently discovered pentapeptide, primarily isolated from saliva. It acts as an inhibitor of the enzymes that perform degradation of endogenous antinociceptive molecules enkephalins, affecting nociceptive signal transduction. This may be of special importance since some intraoral complications of T2DM (e.g. burning mouth) may have underlying peripheral neural changes as a pathophysiological mechanism. Against this background, the aim of the study is to detect the presence and levels of mentioned signal molecules in saliva of patients with and without T2DM.

Conditions

Interventions

TypeNameDescription
OTHERsaliva samples collectingnon-invasive collection of unstimulated whole saliva by spitting method into sterile plastic container

Timeline

Start date
2024-04-01
Primary completion
2024-06-30
Completion
2024-06-30
First posted
2024-03-25
Last updated
2024-07-25

Locations

1 site across 1 country: Serbia

Source: ClinicalTrials.gov record NCT06327503. Inclusion in this directory is not an endorsement.